Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 15-Feb-2013

Biocon has inked a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialization of generic versions of its three insulin analog products.

Mylan will be eligible for the rights to develop and market Biocon\'s Glargine (the generic version of Sanofi\'s Lantus [R]), Lispro (the generic version of Eli Lilly\'s Humalog [R]) and Aspart (the generic version of Novo Nordisk\'s NovoLog [R]).

In order to introduce the product in the market, Mylan and Biocon will share development, capital and certain other costs. Mylan will be eligible for exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the European Union and the European Free Trade Association countries with a profit sharing deal with Biocon.

In other markets across the world, Mylan will have co-exclusive commercialization rights with Biocon.

Chairman and managing director at Biocon, Kiran Mazumdar-Shaw said, “Mylan is a natural preferred partner for our portfolio of generic insulin analogs and this collaboration further strengthens our existing successful partnership. We are excited to team up with Mylan to be able to cost effectively address the disease and economic burden that diabetes poses to global health. We are confident that together we can build a strong global presence in generic insulin analogs and thereby provide access to affordable therapy options to physicians, healthcare providers and diabetes patients worldwide.”

CEO at Mylan, Heather Bresch said, “This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products. This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential. Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and reduce the economic burden to those battling the disease and to the global healthcare system.”

Go to previous page